Tech Company Financing Transactions

Tikva Allocell Funding Round

On 7/22/2026, Tikva Allocell raised $8 million in Series A investment from Kantharos Capital and private investors.

Transaction Overview

Company Name
Announced On
7/22/2026
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors

Kantharos Capital (Lead Investor)

Proceeds Purpose
The company intends to use the funds to further enhance its IND-enabling activities and a planned year-end 2026 Investigational New Drug (IND) submission for TAVST01, its lead candidate for B7-H3-positive solid tumors.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
61 Biopolis Dr, Proteos
Singapore, 138673
Singapore
Phone
Undisclosed
Email Address
Overview
Tikva Allocell is focused on creating therapy using our proprietary IP protected platform to drive the next breakthrough in cancer therapy. At Tikva Allocell we inspire hope today, for a better tomorrow. Tikva Allocell is established by a seasoned cell therapy development team with practical knowledge and experience, to develop effective, available and affordable "off-the-shelf" T cell therapies by leveraging excellent safety profile of Allogeneic Epstein-Barr Virus (EBV)-Specific T cells (ALLO EBVST) and proprietary IP protected technologies that enhance the T cell performance to treat cancer.
Profile
Tikva Allocell LinkedIn Company Profile
Social Media
Tikva Allocell Company Twitter Account
Company News
Tikva Allocell News
Facebook
Tikva Allocell on Facebook
YouTube
Tikva Allocell on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Ivan Horak
  Ivan Horak LinkedIn Profile  Ivan Horak Twitter Account  Ivan Horak News  Ivan Horak on Facebook
Chief Operating Officer
Craig Loren
  Craig Loren LinkedIn Profile  Craig Loren Twitter Account  Craig Loren News  Craig Loren on Facebook
Co-Founder
Malcolm Brenner
  Malcolm Brenner LinkedIn Profile  Malcolm Brenner Twitter Account  Malcolm Brenner News  Malcolm Brenner on Facebook
Co-Founder
Helen Heslop
  Helen Heslop LinkedIn Profile  Helen Heslop Twitter Account  Helen Heslop News  Helen Heslop on Facebook
Co-Founder
Cliona Rooney
  Cliona Rooney LinkedIn Profile  Cliona Rooney Twitter Account  Cliona Rooney News  Cliona Rooney on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/22/2026: StrongestLayer venture capital transaction
Next: 7/22/2026: Candid Health venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary